brand names of glp 1 drugs types GLP-1 Receptor Agonists: An Alternative for Rapid-Acting Insulin? Innovative Primary Care Helps Patients

12 Another limitation is the variability of the available literature, which includes different research designs (RCTs, cohorts, casecontrol studies)

Inclusion criteria: Studies on GLP-1 and inflammation Arthritis-related experimental models Publications from 20052025 Exclusion criteria: Non-peer-reviewed articles Studies lacking quantitative data Researchers extracted data about cytokine levels, receptor expression, and cartilage outcomes

The study showed significant differences in BMI reduction between treatment groups

The FDA is expected to issue its decision by no later than March 2026

doi: 10.1210/en.2019-00101 146 RosenfieldRLEhrmannDA